What is Granulation Technology?
Granulation Technology, Inc. (GTI) operates as a chemical and pharmaceutical manufacturing and distribution entity, focusing on advanced product development solutions designed to enhance drug development portfolios. GTI's comprehensive service offerings encompass formulation development, analytical development, and manufacturing, all conducted under stringent Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) standards. The company boasts a team of seasoned scientific professionals and serves a diverse clientele, from emerging businesses to established Fortune 500 corporations. Its product line includes notable FDA-approved medications such as Prednisone, Carisoprodol, and Methocarbamol tablets, highlighting its capability in bringing critical pharmaceutical products to market.
How much funding has Granulation Technology raised?
Granulation Technology has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Granulation Technology
PPP
Public-Private Partnership
What's next for Granulation Technology?
With the recent influx of capital from a major strategic investment, Granulation Technology is poised for accelerated expansion and innovation. The substantial total funding of $150K indicates a strong investor confidence in GTI's business model and its capacity to scale operations. This backing is likely to fuel further research and development into novel drug formulations, enhance manufacturing capabilities to meet growing demand, and potentially expand its market reach into new therapeutic areas or geographical regions. The company's focus on GLP and GMP compliance positions it favorably for continued growth in the highly regulated pharmaceutical industry.
See full Granulation Technology company page
